Double-sided aspheric diffractive multifocal lens, manufacture, and uses thereof

Information

  • Patent Grant
  • 11963868
  • Patent Number
    11,963,868
  • Date Filed
    Thursday, May 27, 2021
    3 years ago
  • Date Issued
    Tuesday, April 23, 2024
    7 months ago
Abstract
A double-sided aspheric diffractive multifocal lens and methods of manufacturing and design of such lenses in the field of ophthalmology. The lens can include an optic comprising an aspheric anterior surface and an aspheric posterior surface. On one of the two surfaces a plurality of concentric diffractive multifocal zones can be designed. The other surface can include a toric component. The double-sided aspheric surface design results in improvement of the modulation transfer function (MTF) of the lens-eye combination by aberration reduction and vision contrast enhancement as compared to one-sided aspheric lens. The surface having a plurality of concentric diffractive multifocal zones produces a near focus, an intermediate focus, and a distance focus.
Description
FIELD

The present disclosure relates generally to ophthalmic lenses, and more specifically to a novel double-sided aspheric diffractive multifocal lens, design, manufacture, and uses thereof.


BACKGROUND

Ophthalmology is the field of medicine directed to the anatomy, physiology and diseases of the human eye. The anatomy of the human eye is rather complex. The main structures of the eye include the cornea, a spherical clear tissue at the outer front of the eye; the iris, which is the colored part of the eye; the pupil, an adaptable aperture in the iris that regulates the amount of light received in the eye; the crystalline lens, a small clear disk inside the eye that focuses light rays onto the retina; the retina is a layer that forms the rear or backside of the eye and transforms sensed light into electrical impulses that travel through the optic nerve to the brain. The posterior chamber, i.e., the space between the retina and the lens, is filled with aqueous humour, and the anterior chamber, i.e., the space between the lens and the cornea, is filled with vitreous humour a clear, jelly-like substance.


The natural crystalline lens has a flexible, transparent, biconvex structure, and together with the cornea, operates to refract light to be focused on the retina. The lens is flatter on its anterior side than on its posterior side and its curvature is controlled by the ciliary muscles to which the lens connects by suspensory ligaments, called zonules. By changing the curvature of the lens, the focal distance of the eye is changed so as to focus on objects at various distances. To view an object at a short distance from the eye, the ciliary muscles contract, and the lens thickens, resulting in a rounder shape and thus high refractive power. Changing focus to an object at a greater distance requires the relaxation of the lens and thus increasing the focal distance. This process of changing curvature and adapting the focal distance of the eye to form a sharp image of an object at the retina is called accommodation.


In humans, the refractive power of the crystalline lens in its natural environment is approximately 18-20 diopters, roughly one-third of the total optical power of the eye. The cornea provides the remaining 40 diopters of the total optical power of the eye.


With the ageing of the eye, the opaqueness of the lens diminishes, called a cataract. Some diseases like diabetes, trauma, some medications, and excessive UV light exposure may also cause a cataract. A cataract is painless and results in a cloudy, blurry vision. Treatments for cataracts include surgery, by which the cloudy lens is removed and replaced with an artificial one, generally called an intraocular lens (IOL or IOLs).


Another age-related effect is called presbyopia, which is manifested by difficulty in reading small print or seeing nearby pictures clearly. Presbyopia generally is believed to be caused by a thickening and loss of flexibility of the natural lens inside the eye. Age-related changes also take place in the ciliary muscles surrounding the lens. With less elasticity it becomes harder to focus at objects close to the eye.


A variety of intraocular lenses are also employed for correcting other visual disorders, such as myopia or nearsightedness, when the eye is unable to see distant objects caused by the cornea having too much curvature, for example. The effect of myopia is that distant light rays focus at a point in front of the retina, rather than directly on its surface. Hyperopia or farsightedness, caused by an abnormally flat cornea, such that light rays entering the eye focus behind the retina, not allowing to focus on objects that are close, and astigmatism, which is another common cause of visual difficulty in which images are blurred due to an irregularly shaped cornea.


In the majority of cases, intraocular lenses are implanted in a patient's eye during cataract surgery, to replace the natural crystalline lens and compensate for the loss of optical power of the removed lens. Modern IOL optics are designed to have a multifocal optic for providing short, intermediary and distance vision of objects, also called multifocal IOL, or more specific trifocal lenses. Presbyopia is corrected by eyeglasses or contact lenses and patient's may also opt for multifocal optics. In some cases, an IOL can include diffractive structures to have not only a far-focus power but also a near-focus power, thereby providing a degree of pseudo-accommodation. However, a variety of aberrations, such as spherical and astigmatic aberrations, can adversely affect the optical performance of such lenses. For example, spherical aberrations can degrade vision contrast, especially for large pupil sizes.


Accordingly, what is needed is intraocular lenses that can simultaneously provide a near focus, an intermediate focus, and a distance focus, which can also address adverse effects such as spherical and astigmatic aberrations, thereby providing enhanced contrast and improved visual acuity.


SUMMARY

The present disclosure is related to a double-sided aspheric diffractive multifocal lens, which can eliminate spherical and astigmatic aberrations and provide enhanced contrast and improved visual acuity. In some embodiments, the diffractive multifocal lens can include a lens body, the lens body can include: a first aspheric surface; and a second aspheric surface including a central zone and a plurality of diffractive elements comprising concentric annular zones extending in a radial direction, each concentric annular zone having a periodically structured curve comprising two smooth turning points between two sharp turning points, thereby producing a near focus (f2), an intermediate focus (f1), and a distance focus (f0).


In some embodiments, the first aspheric surface is anterior surface, and the second aspheric surface is posterior surface. In some embodiments, the first aspheric surface can include a toric component. In some embodiments, a height profile of the first aspheric surface and/or the second aspheric surface is represented by:








Z
asp



(
r
)


=



cr
2


1
+


1
-


(

1
+
k

)



c
2



r
2






+




i
=
2

n




A
i



r

2

i










wherein Zasp is the height profile of the aspheric structure, r is the radial distance in millimeters, c is the curvature, k is the conic constant, and Ai is high order aspheric coefficients.


In some embodiments, a height profile of the diffractive elements is represented by:








Z
diff



(
r
)


=



Φ

(
n
)




(
r
)


×

λ


n
1

-

n
0









wherein λ is the design wavelength, Φ(n)(r) is phase profile, n1 is refractive index of lens material, and n0 is refractive index of a medium covering the lens.


In some embodiments, phase profile Φ(n)(r) can be represented as:








Φ

(
n
)




(
r
)


=


A
×

sin


(


(


B
×


r
-

r
n




r

n
+
1


-

r
n




+
C

)

×
π

)



+
D






wherein r is the radial distance of the lens in millimeter, rn is radius of nth zone, rn+1 is radius of (n+1)th zone, and A, B, C and D, are light distribution parameters. A is amplitude; B is the period as








2





π

B



;






C is phase shift; D is vertical shift.


In some embodiments, phase profile Φ(n)(r) can be in the range of −4π≤Φ(n)(r)≤4π. In some embodiments, the distance focus (f0), the intermediate focus (f1), and the near focus (f2) are in the range of:








0





D



1

f
0




55





D


,


1





D




1

f
1


-

1

f
0





2.5





D


,


2





D




1

f
2


-

1

f
0





5






D
.







In some embodiments, the diffractive multifocal lens can be an intraocular lens (IOL). In some embodiments, the diffractive multifocal lens can further include a pair of haptics extended outwardly from the lens body. In some embodiments, the IOL is a posterior chamber IOL, and the posterior chamber IOL is configured to be implanted into capsular bag of a human eye.


In some embodiments, the present disclosure is directed to a method of treating an ophthalmic disease or disorder in a subject, the method can include implanting into an eye of the subject a diffractive multifocal lens comprising a lens body, the lens body can include a first aspheric surface; and a second aspheric surface comprising a central zone and a plurality of diffractive elements comprising concentric annular zones extending in a radial direction, each concentric annular zone having a periodically structured curve comprising two smooth turning points between two sharp turning points.


In some embodiments, the present disclosure is directed to a method of manufacturing a diffractive multifocal lens, the method can include (a) manufacturing a first aspheric surface optionally comprising a toric component; (b) manufacturing a second aspheric surface; and (c) generating a central zone and diffractive elements comprising a plurality of concentric annular zones on the second aspheric surface, each concentric annular zone having a periodically structured curve comprising two smooth turning points between two sharp turning points, thereby producing a near focus (f2), an intermediate focus (f1), and a distance focus (f0). In some embodiment, the method can further include performing an in situ image quality analysis to ensure the performance meets the pre-established quality criteria.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A illustrates the top view of a double-sided aspheric multifocal diffractive IOL, according to some embodiments of the present disclosure;



FIG. 1B shows the cross-sectional view of a double-sided aspheric multifocal diffractive IOL, according to some embodiments of the present disclosure;



FIG. 2A illustrates a blow-up view of the lens body of the IOL, according to some embodiments of the present disclosure;



FIG. 2B illustrates the height profile of the diffractive elements, according to some embodiments of the present disclosure;



FIG. 2C illustrates the height profile of the diffractive elements, according to another embodiment of the present disclosure;



FIG. 3A illustrates the optical performance (modulation transfer function, MTF) at a 3 mm aperture and at a resolution measurement of 50 LP/mm by varying parameters according to a first embodiment of the present disclosure;



FIG. 3B illustrates the height profile of the aspheric and diffractive combination structure according to a first embodiment of the present disclosure;



FIG. 4A illustrates the optical performance (MTF) at a 3 mm aperture and at a resolution measurement of 50 LP/mm by varying parameters according to a second embodiment of the present disclosure;



FIG. 4B illustrates the height profile of the aspheric and diffractive combination structure according to a second embodiment of the present disclosure;



FIG. 5A illustrates the optical performance (MTF) at a 3 mm aperture and at a resolution measurement of 50 LP/mm by varying parameters according to a third embodiment of the present disclosure;



FIG. 5B illustrates the height profile of the aspheric and diffractive combination structure according to a third embodiment of the present disclosure; and



FIG. 6 is a flowchart illustrating the design and manufacture of the double-sided aspheric multifocal diffractive IOL, according to some embodiments of the present disclosure.





DETAILED DESCRIPTION

The present disclosure is related to a double-sided aspheric diffractive multifocal lens and methods of designing and manufacturing of such lenses in the field of ophthalmology. The lens can include an aspheric anterior surface and an aspheric posterior surface. One of the two surfaces can include a plurality of concentric diffractive multifocal zones. The other surface can optionally include a toric component. The double-sided aspheric surface design results in an improvement of the modulation transfer function (MTF) of the lens-eye combination by aberration reduction and vision contrast enhancement as compared to one-sided aspheric lens. The surface having a plurality of concentric diffractive multifocal zones can produce a near focus, an intermediate focus, and a distance focus.


Multifocal IOLs are commonly used to treat presbyopia, a condition in which the eye exhibits a progressively diminished ability to focus on near objects. Human beings become presbyopic due to aging, and the effect typically becomes noticeable starting at about the age of 40-45 years old, when they discover they need reading glasses. Presbyopic individuals who wear corrective lenses may then find that they need two separate prescriptions, preferably within the same bifocal lens, one for reading (near) and another for driving (distance). A trifocal lens can further improve vision at intermediate distances, for example, when working at a computer.


Diffractive IOLs can have a repeating structure that may be formed in the surface of an optical element by a fabrication method such as, for example, cutting the surface using a lathe that may be equipped with a cutting head made of a hard mineral such as diamond or sapphire; direct write patterning using a high energy beam such as a laser beam or electron beam or a similar method of ablating the surface; etching the surface using a photolithographic patterning process; or molding the surface. The diffractive structure is typically a series of concentric annular zones, which requires each zone to become progressively narrower from the center to the edge of the lens. There may be, for example, about 5 to 30 zones between the center and the edge of the lens. The surface profile within each zone is typically a smoothly varying function such as an arc, a parabola, or a line. At the outer periphery of each zone there is a discrete step in the vertical surface profile. The resulting surface structure can act as a circularly symmetric diffraction grating that disperses light into multiple diffraction orders, each diffraction order having a consecutive number, zero, one, two, three and so forth.


Diffractive IOLs lenses may be used for correcting presbyopia. In such an application, the lens can include one refractive surface and one diffractive surface. In practice, the light energy passing through a diffractive lens is typically concentrated into one, two, or three diffractive orders, while contributing an insignificant amount of light energy to other diffractive orders.


Existing designs for multifocal IOLs use either refractive optics, a combination refractive/diffractive design, or diffractive lenses that direct light into a single diffractive order. However, the fabrication of such IOLs can be time-consuming and expensive. Therefore, there is a need for improved ophthalmic lenses, particularly for improved diffractive IOLs that can be more readily fabricated.


The present disclosure is directed to an intraocular lens (IOL), which provides an extended vision range. FIG. 1A shows a top view of a double-sided aspheric multifocal diffractive IOL 100, according to some embodiments of the present disclosure. FIG. 1B shows a cross-sectional view of the double-sided aspheric multifocal diffractive IOL 100, according to some embodiments of the present disclosure. IOL 100 can include a light transmissive circular disk-shaped lens body 101 with an optic diameter of 106 and a center thickness 110, as well as a pair of haptics 102 as flexible support for the IOL when implanted into patient's eye, with a total outer diameter 107. Lens body 101 can include an anterior surface 108, a posterior surface 109, a central zone 103 and a plurality of diffraction elements 104 on the posterior surface 109. Lens body 101 can include an optical axis 105 extending transverse to the anterior surface 108 and posterior surface 109. A skilled artisan in the art will appreciate that the optical axis 105 is a virtual axis for purposes of referring to the optical properties of IOL 100. The pair of haptics 102 can be extended outwardly from the lens body 101 for supporting the IOL 100 after being implanted in the human eye. In some embodiments, the haptics 102 of IOL 100 can hold the IOL in place in the capsular bag.


In some embodiments, lens body 101 can take the shape of biconvex shape. Other shapes of lens body 101 can include, but are not limited to, plano-convex, biconcave, plano-concave shape, or combinations of convex and concave shapes. In some embodiments, both anterior surface 108 and posterior surface 109 can feature an aspheric structure, providing a double-sided asphericity for IOL 100.


Diffractive element 104 can include diffractive rings or steps or also known as diffractive zones having a characteristic radial separation to produce constructive interference at characteristic foci on the optic area of the IOL. In some embodiments, diffractive elements 104 can include about 3 to about 30 diffractive rings/zones. In some embodiments, diffractive elements 104 can include about 5, 10, 15, 20, or 25 diffractive rings/zones. The IOL can contain diffractive elements on one of the surfaces or both surfaces of the lens. In some embodiments, the diffractive elements 104 can be placed on the posterior surface of the IOL. In some embodiments, the diffractive elements can be placed at the posterior surface, because there is less light scattering effect at the posterior surface than at the anterior surface. The plurality of diffractive elements 104 can include rings or zones extending concentrically with respect to the optical axis 105 through the central zone 103 over at least part of the posterior surface 109 of the lens body 101. The diffraction elements 104 can provide a focal point of far, intermediate, and/or near distance. In some embodiments, diffraction elements 104 are not limited to concentric circular or annular ring-shaped zones, but can include concentric elliptic or oval shaped zones.


In some embodiments, the optic diameter 106 of lens body 101 can be about 4 to about 8 mm, while the total outer diameter 107 of IOL 100 including the haptics 102 can be about 9 to about 18 mm. Lens body 101 can have a center thickness 110 of about 0.8 to about 1.2 mm. Although the embodiment in FIGS. 1A and 1B deals with a posterior chamber IOL, other ophthalmic lenses, including multifocal diffractive contact lenses or eye glass lenses, could also benefit from the same approach. When used for ophthalmic multifocal contact lenses and spectacle or eye glass lenses, haptics 102 are not provided.


The amount of correction that an ophthalmic lens provides is called optical power, and is expressed in Diopter (D). The optical power is calculated as the inverse of a focal distance f measured in meters, which can be a respective focal distance from the lens to a respective focal point for far, intermediate, or near vision. Lens body 101 in the double-sided aspheric shape of the present disclosure can provide a base optical power of about 10 to about 25 D. In some embodiments, lens body 101 can provide a base optical power of about 12, 14, 16, 18, 20, 22, or 24 D. The plurality of diffractive elements 104 can provide added power of f1=f0+2.2D and f2=f0+3.3D.


IOLs can be made of flexible material which permits a reduction of their overall apparent girth by temporary deformation, facilitating their insertion through the cornea, thereby advantageously enabling the use of a corneal incision of concomitantly reduced size. In some embodiments, the lens body can include polypropylene, polycarbonate, polyethylene, acryl-butadiene styrene, polyamide, polychlorotrifluoroethylene, polytetrafluoroethylene, polyvinyl chloride, polyvinylidene fluoride, polyvinylchloride, polydimethylsiloxane, polyethylene terephthalate, ethylene tetrafluoroethylene, ethylene chlorotrifluoroethylene, perfluoroalkoxy, polymethylpentene, polymethylmethacrylate, polystyrene, polyetheretherketone, tetrafluoroethylene, polyurethane, poly(methyl methacrylate), poly (2-hydroxyethyl methacrylate), nylon, polyether block amide, silicone or a mixture thereof.


In some embodiments, the lens body can include a hydrophilic polymer made of monomers selected from the group consisting of: 2-acrylamido-2-methylpropane sulfonic acid, 2-hydroxyethyl methacrylate, N-vinylpyrrolidone, vinylbenzyltrimethyl ammonium salt, diethylaminoethyl methacrylate, dimethylaminoethyl acrylate, dimethylaminoethyl methacrylate, diethyl aminoethyl acrylate, diethylaminomethyl methacrylate, tertiary butylaminoethyl acrylate, tertiary-butylaminoethyl methacrylate and dimethylaminopropylacrylamide, acrylic acid, methacrylic acid, styrenesulfonic acid and salts thereof, hydroxypropyl acrylate, vinylpyrrolidone, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, ethylene glycol dimethacrylate, ethylene glycol diacrylate, triethylene glycol diacrylate and triethylene glycol methacrylate. In some embodiments, these hydrophilic monomers are surface grafted onto the polymeric matrix in the previous paragraph to make the lens body. In some embodiments, the IOL of the present disclosure can be made of polymeric compositions according to U.S. Pat. No. 10,494,458, which is incorporated herein by reference in its entirety.


The haptics of the IOL according to the present disclosure can be made of polymeric materials including, but not limited to polymethacrylate, polypropylene, polyethylene, polystyrene, and polyacrylate.


The surface of the IOL can include a spheric, aspheric, or toric element. Spheric surfaces can cause spherical aberration, which is a type of optical imperfection that can cause increased glare, and reduced overall quality of vision especially in low light and darkness. Aspheric lenses can correct spherical aberration. Aspherical IOL can provide improved contrast sensitivity, enhanced functional vision and superior night driving ability.


A toric element is typically used for astigmatic eye correction. Generally, astigmatism is an optical defect in which vision is blurred due to the ocular inability to focus a point object into a sharply focused image on the retina. This may be due to an irregular curvature of the cornea and/or lens. The refractive error of the astigmatic eye stems from a difference in degree of curvature, and therefore in degree of refraction, of the different meridians of the cornea and/or the crystalline lens, which causes the eye to have two focal points, one correspondent to each meridian. As used herein, a meridian includes one of two axes that subtend a curved surface, such as the prime meridian on the earth, for example. Meridians may be orthogonal. By way of example, the meridians of the earth may be any orthogonal line of longitude and any line of latitude that curve about the surface of the earth.


For example, in an astigmatic eye, an image may be clearly focused on the retina in the horizontal (sagittal) plane, but may be focused behind the retina in the vertical (tangential) plane. In the case where the astigmatism results only from the cornea, the two astigmatism meridians may be the two axes of the cornea. If the astigmatism results from the crystalline lens, the two astigmatism meridians may be the two axes of the crystalline lens. If the astigmatism results from a combination of the cornea and the crystalline lens, the two astigmatism meridians may be the respective axes of the combined lenses of the cornea and the crystalline lens.


An astigmatism arising from the cornea or crystalline lens, or the combination of the two lenses, may be corrected by a lens including a toric component. A toric surface resembles a section of the surface of a football, for which there are two regular radii of curvature, one smaller than another. These radii may be used to correct the defocus in the two meridians of the astigmatic eye. Thus, blurred vision caused by astigmatism may be corrected by corrective lenses or laser vision correction, such as glasses, hard contact lenses, contact lenses, and/or an IOL, providing a compensating optic specifically rotated around the optical axis.


In some embodiments, the IOL according to the present disclosure can provide far vision for viewing objects at distances ranging from about infinity to about 4 meters (m). In some embodiments, the IOL of the present disclosure can provide near vision for viewing objects at distances less than about 0.4 m. In some embodiments, the IOL of the present disclosure can provide intermediate vision for viewing objects at distances in a range of about 0.4 to about 1 m, about 2 m, about 3 m, or about 4 m. As a result, the IOL of the present disclosure can advantageously provide a degree of accommodation for different distance ranges, typically referred to as pseudo-accommodation. In some embodiments, when implanted into a patient's eye, the combined power of the eye's cornea and the near, intermediate, and far power of the IOL of the present disclosure can allow focusing light emanating from objects within a near, an intermediate, and a far distance range of the patient onto the retina. In some embodiments, the distance focus (f0), intermediate focus (f1), and near focus (f2) provided by the IOL of the present disclosure can have the following ranges:








0





D



1

f
0




55





D


,


1





D




1

f
1


-

1

f
0





2.5





D


,


and





2





D




1

f
2


-

1

f
0





5






D
.








FIG. 2A shows a blow-up view of lens body 101, including anterior surface 108, posterior surface 109, optical axis 105, central zone 103 and the plurality of diffraction elements 104 generated on the posterior surface. The central zone 103 and diffraction elements 104 are further illustrated in FIG. 2B. The central zone begins from the 0th Fresnel zone (from d0 to d1). The diffraction elements are configured as periodically structured smooth curve (from d2 to d3), each periodic structure of the diffraction elements contains two smooth turning points (e1, e2) in between two sharp turning points (d2, d3). FIG. 2C illustrates another embodiment of the present disclosure, by smoothing out two smooth turning points (e1, e2), and their periodically corresponding turning points.


This diffractive structure embodied on the IOLs of the present disclosure can be designed using Equations (I) to (IV) as discussed below.


Pupil Function. A pupil function is a lens characteristic function that describes the physical effect of a lens by which it is possible to change the state of light made incident on the lens, and in specific terms, is represented by the product of the amplitude function A(r) and the exponential function of the phase function Φ(n)(r) as noted in Equation (I) below.

T(r)=A(r)ei(Φ(n)(r))  Equation (I)

    • T(r): pupil function
    • A(r): amplitude function
    • Φ(n)(r): phase function
    • n: natural number


Phase Function. A phase function is defined as the function that mathematically expresses the physical effect provided in a lens such as giving changes in the phase of incident light on a lens (position of wave peaks and valleys) using any method. The variable of the phase function is mainly expressed by position r in the radial direction from the center of the lens, and the phase of light made incident on the lens at the point of the position r undergoes a change by the phase function Φ(n)(r) and is emitted from the lens. In specific terms, this is represented by an r-Φ coordinate system. In the present disclosure, phase is noted as Φ, and the unit is radians. One wavelength of light is represented as 2π radians, and a half wavelength as π radians, for example. A distribution of phase in the overall area in which the phase function is provided expressed in the same coordinate system is called a phase profile, or is simply called a profile or zone profile. With an r axis of Φ=0 as a reference line, this means that the light made incident at the point of Φ=0 is emitted without changing the phase. Also, for this reference line, when a positive value is used for Φ, this means that progress of the light is delayed by that phase amount, and when a negative value is used for Φ, this means that progress of the light is advanced by that phase amount. In an actual ophthalmic lens, a refracting surface for which a diffractive structure is not given corresponds to this reference line (surface). Light undergoes a phase change based on this phase function and is emitted from the lens.


Amplitude Function. An amplitude function is the function expressed by A(r) in Equation (I) noted above. In the present disclosure, this is defined as a function that represents the change in the light transmission amount when passing through a lens. The variable of the amplitude function is represented as position r in the radial direction from the center of the lens, and represents the transmission rate of the lens at the point of position r. Also, the amplitude function is in a range of 0 or greater and 1 or less, which means that light is not transmitted at the point of A(r)=0, and that incident light is transmitted as it is without loss at the point of A(r)=1.


Zone. In the present disclosure, a zone is used as the minimum unit in a diffractive structure, element, or diffraction grating provided in a lens.


The height profile of the diffractive structure (Zdiff) on the IOL can be calculated based on Equation (II) below.











Z
diff



(
r
)


=



Φ

(
n
)




(
r
)


×

λ


n
1

-

n
0








Equation






(
II
)










    • Zdiff(r): height profile of the diffractive structure

    • Φ(n)(r): phase function

    • λ: design wavelength

    • n1: refractive index of the lens material

    • n0: refractive index of the medium covering the lens





The radius of a particular diffractive zone (rn) can be calculated based on Equation (III) below.

rn=√{square root over (2×λ×n×f)}  Equation (III)

    • rn: radius of the nth zone
    • λ: design wavelength
    • f: reciprocal of add power


Phase function (Φ(n)(r)) can be calculated via Equation (IV) below.











Φ

(
n
)




(
r
)


=


A
×

sin


(


(


B
×


r
-

r
n




r

n
+
1


-

r
n




+
C

)

×
π

)



+
D





Equation






(
IV
)










    • Φ(n)(r): phase function

    • r: is the radial distance from a center of lens

    • rn: radius of the nth zone

    • rn+1: radius of the (n+1)th zone

    • wherein A, B, C and D, are the light distribution parameters. A is the amplitude; B is the period as











2





π

B



;







    •  C is the phase shift, if it is +C, it shifts left, if the phase shift is −C, it shifts right; D is the vertical shift, if it is +D, the function moves up, if it is −D, then the function moves down.





The double-sided aspheric structure (anterior and posterior of the optic area of the IOL) is for the correction of the spherical aberration of the lens. The height profile of the aspheric base structure (Zasp) of the lens can be calculated according to the following Equation (V):











Z
asp



(
r
)


=



cr
2


1
+


1
-


(

1
+
k

)



c
2



r
2






+




i
=
2

n




A
i



r

2

i









Equation






(
V
)










    • Zasp: is the height profile of the aspheric structure

    • r: is the radial distance from a center of lens

    • k: is the conic constant

    • c: is the curvature

    • Ai: is the high order aspheric coefficient





When both aspheric and diffractive structures are placed onto the same surface (anterior surface and/or posterior surface of the IOL), according to some embodiments of the present disclosure, the height profile of the combination structure (Ztotal) will be the summation of the height profile of the aspheric structure (Zasp) and the height profile of the diffractive structure (Zdiff), as calculated according to the below Equation (VI).

Ztotal(r)=Zasp(r)+Zdiff(r)  Equation (VI)

    • Zdiff: height profile of the diffractive structure
    • Zaspheric: height profile of the aspheric structure
    • Ztotal: height profile of the combination structure, i.e. the lens body


In some embodiments, the above-described lens can be contact lens or IOL. In some embodiments, the IOL can be intracorneal IOL, anterior chamber IOL or posterior chamber IOL. In some embodiments, the IOL can be posterior chamber IOL. While the haptic arms are illustrated in the embodiment, any suitable haptics fixation structure for the capsular bag or the ciliary sulcus compatible with posterior chamber implantation can also be used in a posterior chamber IOL.


A way of estimating the optical priority of an intraocular lens comprises determining experimentally its modulation transfer function (MTF). The MTF of an optical system can be measured according to Annex C of ISO 11979-2, which reflects the proportion of the contrast which is transmitted through the optical system for a determined spatial frequency of a test pattern, which frequency is defined as “cycles/mm” or “LP/mm”, in which “LP” indicates “line pairs.” Generally, the contrast decreases with an increase in spatial frequency.


All publications, patents, and patent applications mentioned in the present disclosure are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, it will be understood that modifications and variations are encompassed within the spirit and scope of the instant disclosure. The preferred methods and materials are now described.


Presented below are examples discussing different embodiments of the IOLs contemplated for the discussed applications. The following examples are provided to further illustrate the embodiments of the present disclosure, but are not intended to limit the scope of the disclosure. While they are typical of those that might be used, other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.


EXAMPLES
Example 1
MTF and Height Profile of the IOL According to the First Embodiment of the Present Disclosure

From Equation (IV), by varying parameters A, B, C and D, and controlling the distance focus (f0), the intermediate focus (f1), and the near focus (f2), the optical performance (modulation transfer function, MTF) at a 3 mm aperture and at a resolution measurement of 50 line pairs per millimeter (LP/mm) is shown in FIG. 3A. The parameters of A, B, C and D are varied according to Table 1 below.









TABLE 1







Variation of parameters A-D in a first


embodiment of the present disclosure.














A
B
C
D

















Ring 1
0.6
0.5
1
−0.42



Ring 2
0.41
0.5
0.5
0.24



Ring 3
−0.1
1
0.5
−0.07



Ring 4
0.45
0.5
1
−0.42



Ring 5
0.41
0.5
0.5
0.24



Ring 6
−0.1
1
0.5
−0.07



Ring 7
0.45
0.5
1
−0.42



Ring 8
0.41
0.5
0.5
0.24



Ring 9
−0.1
1
0.5
−0.07



Ring 10
0.45
0.5
1
−0.42



Ring 11
0.41
0.5
0.5
0.24



Ring 12
−0.1
1
0.5
−0.07



Ring 13
0.45
0.5
1
−0.42



Ring 14
0.41
0.5
0.5
0.24



Ring 15
−0.1
1
0.5
−0.07










The curve in FIG. 3A shows three peaks corresponding to a distance focus at about 14.0 D, an intermediate focus at about 16.2 D, and a near focus at about 17.3 D, respectively. The minimum value between f1 and f2 is about 50% of the MTF of f1.


The Ztotal(r) height profile of the aspheric and diffractive combination structure is shown in FIG. 3B. The height is depicted at μm scale along the vertical axis. The optical axis, running through the center of the lens body, is assumed to be at a radial position r=0, whereas the radial distance r measured in outward direction from the optical axis is expressed in mm along the vertical axis.


Example 2
MTF and Height Profile of the IOL According to the Second Embodiment of the Present Disclosure

From Equation (IV), by varying parameters A, B, C and D, and controlling the f0, f1 and f2, the optical performance (MTF) at a 3 mm aperture and at a resolution measurement of 50 line pairs per millimeter (LP/mm) is shown in FIG. 4A. The parameters of A, B, C and D are varied according to Table 2 below. The Ztotal(r) height profile of the aspheric and diffractive combination structure is shown in FIG. 4B.









TABLE 2







Variation of parameters A-D in a second


embodiment of the present disclosure.














A
B
C
D

















Ring 1
0.68
0.5
1
−0.38



Ring 2
0.36
0.5
0.5
0.22



Ring 3
−0.12
1
0.5
−0.02



Ring 4
0.48
0.5
1
−0.38



Ring 5
0.36
0.5
0.5
0.22



Ring 6
−0.12
1
0.5
−0.02



Ring 7
0.48
0.5
1
−0.38



Ring 8
0.36
0.5
0.5
0.22



Ring 9
−0.12
1
0.5
−0.02



Ring 10
0.48
0.5
1
−0.38



Ring 11
0.36
0.5
0.5
0.22



Ring 12
−0.12
1
0.5
−0.02



Ring 13
0.48
0.5
1
−0.38



Ring 14
0.36
0.5
0.5
0.22



Ring 15
−0.12
1
0.5
−0.02










The curve in FIG. 4A shows three peaks corresponding to a distance focus at about 24.0 D, an intermediate focus at about 26.2 D, and a near focus at about 27.3 D, respectively. The minimum value between f1 and f2 is about 50% of the MTF of f1.


Example 3
MTF and Height Profile of the IOL According to the Third Embodiment of the Present Disclosure

From Equation (IV), by varying parameters A, B, C and D, and controlling the f0, f1 and f2, the optical performance (MTF) at a 3 mm aperture and at a resolution measurement of 50 line pairs per millimeter (LP/mm) is shown in FIG. 5A. The parameters of A, B, C and D are varied according to the Table 3 below. The Ztotal(r) height profile of the aspheric and diffractive combination structure is shown in FIG. 5B.









TABLE 3







Variation of parameters A-D in a third


embodiment of the present disclosure.












A
B
C
D














Ring 1
0.76
0.5
1
−0.5


Ring 2
0.41
0.5
0.5
0.24


Ring 3
−0.1
1
0.5
−0.07


Ring 4
0.45
0.5
1
−0.42


Ring 5
0.41
0.5
0.5
0.24


Ring 6
−0.1
1
0.5
−0.07


Ring 7
0.45
0.5
1
−0.42


Ring 8
0.41
0.5
0.5
0.24


Ring 9
−0.1
1
0.5
−0.07


Ring 10
0.45
0.5
1
−0.42


Ring 11
0.41
0.5
0.5
0.24


Ring 12
−0.1
1
0.5
−0.07


Ring 13
0.45
0.5
1
−0.42


Ring 14
0.41
0.5
0.5
0.24


Ring 15
−0.1
1
0.5
−0.07









The curve in FIG. 5A shows three peaks corresponding to a distance focus at about 19.0 D, an intermediate focus at about 21.2 D, and a near focus at about 22.3 D, respectively.



FIG. 6 is a flowchart 600 illustrating the design and manufacture of the double-sided aspheric multifocal diffractive IOL, according to some embodiments of the present disclosure. Step 601 manufactures a first aspheric surface optionally including a toric component. Step 602 manufactures a second aspheric surface. Step 603 generates a plurality of concentric diffractive multifocal zones on the second aspheric surface to produce a near focus, an intermediate focus, and a distance focus. Step 604 performs an in situ image quality analysis of the double-sided aspheric diffractive multifocal lens on an ISO Model Eye 2 to measure the through focus MTF using the TRIOPTICS OptiSpheric® IOL PRO 2 up to the pre-established performance criteria.


While the disclosure has been particularly shown and described with reference to specific embodiments, it should be understood by those having skill in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the present disclosure as disclosed herein.


All references referred to in the present disclosure are hereby incorporated by reference in their entirety. Various embodiments of the present disclosure may be characterized by the potential claims listed in the paragraphs following this paragraph (and before the actual claims provided at the end of this application). These potential claims form a part of the written description of this application. Accordingly, subject matter of the following potential claims may be presented as actual claims in later proceedings involving this application or any application claiming priority based on this application. Inclusion of such potential claims should not be construed to mean that the actual claims do not cover the subject matter of the potential claims. Thus, a decision to not present these potential claims in later proceedings should not be construed as a donation of the subject matter to the public.


The embodiments of the disclosure described above are intended to be merely exemplary; numerous variations and modifications will be apparent to those skilled in the art. All such variations and modifications are intended to be within the scope of the present disclosure as defined in any appended claims.

Claims
  • 1. A diffractive trifocal lens comprising a lens body, the lens body comprising: (a) a first aspheric surface; and(b) a second aspheric surface comprising a central zone and a plurality of diffractive elements comprising concentric annular zones extending in a radial direction, each concentric annular zone having a periodically structured curve comprising two smooth turning points between two sharp turning points, wherein a slope of the periodically structured curve changes sign at each of the two smooth turning points in each of the concentric annular zones, thereby producing a near focus (f2), an intermediate focus (f1), and a distance focus (f0),wherein a modulation transfer function (MTF) of the diffractive trifocal lens comprises a first peak at the intermediate focus (f1) and a second peak at the near focus (f2), andwherein a most minimum value of the MTF between the first peak and the second peak is about 50% of a most maximum value of the MTF at the first peak, thereby improving vision contrast between the intermediate focus (f1) and the near focus (f2); andwherein: an optical power of the distance focus (f0) is greater than or equal to 0 diopters and less than or equal to 55 diopters;an optical power of the intermediate focus (f1) is greater than the optical power of the distance focus (f0) by a first difference in optical power that is greater than or equal to 1 diopter and less than or equal to 2.5 diopters; andan optical power of the near focus (f2) is greater than the optical power of the distance focus (f0) by a second difference in optical power that is greater than or equal to 2 diopters and less than or equal to 5 diopters.
  • 2. The diffractive trifocal lens of claim 1, wherein the first aspheric surface is anterior surface.
  • 3. The diffractive trifocal lens of claim 1, wherein the second aspheric surface is posterior surface.
  • 4. The diffractive trifocal lens of claim 1, wherein the first aspheric surface comprises a toric component.
  • 5. The diffractive trifocal lens of claim 1, wherein the diffractive trifocal lens is an intraocular lens (IOL) sized for insertion into a human eye.
  • 6. The diffractive trifocal lens of claim 5, further comprising a pair of haptics extended outwardly from the lens body.
  • 7. The diffractive trifocal lens of claim 5, wherein the IOL is sized for insertion into a posterior chamber of the human eye.
  • 8. The diffractive trifocal lens of claim 7, wherein the posterior chamber IOL is configured to be implanted into a capsular bag of the human eye.
  • 9. A method of treating an ophthalmic disease or disorder in a subject, the method comprising implanting into an eye of the subject the diffractive trifocal lens of claim 1.
  • 10. The method of claim 9, wherein the ophthalmic disease or disorder is selected from the group consisting of cataract and presbyopia.
  • 11. The method of claim 9, wherein the diffractive trifocal lens is an intraocular lens (IOL) sized for insertion into the subject's eye.
  • 12. The method of claim 11, wherein the diffractive trifocal lens further comprises a pair of haptics extended outwardly from the lens body.
  • 13. The method of claim 11, wherein the IOL is implanted into a capsular bag of the subject's eye.
  • 14. A method of manufacturing the diffractive trifocal lens of claim 1, the method comprising: (a) manufacturing the first aspheric surface optionally comprising a toric component;(b) manufacturing the second aspheric surface; and(c) generating the central zone and the diffractive elements comprising the plurality of concentric annular zones on the second aspheric surface, each concentric annular zone having the periodically structured curve comprising the two smooth turning points between the two sharp turning points, wherein the slope of the periodically structured curve changes sign at each of the two smooth turning points in each of the concentric annular zones,thereby producing the near focus (f2), the intermediate focus (f1), and the distance focus (f0).
  • 15. The method of claim 14, further comprising: performing an in situ image quality analysis to measure the modulation transfer function (MTF) of the trifocal lens using pre-established quality criteria.
CROSS-REFERENCE TO RELATED APPLICATIONS

The application claims benefit of priority under 35 U.S.C. § 119(e) of U.S. Ser. No. 63/032,892, filed Jun. 1, 2020, the entire content of which is incorporated by reference in its entirety.

US Referenced Citations (896)
Number Name Date Kind
2163130 Pellow Jun 1939 A
4402579 Poler Sep 1983 A
4450593 Poler May 1984 A
4466858 Poler Aug 1984 A
4473434 Poler Sep 1984 A
4619657 Keates et al. Oct 1986 A
4720286 Bailey et al. Jan 1988 A
4846913 Frieder et al. Jul 1989 A
4955904 Atebara et al. Sep 1990 A
4981342 Fiala Jan 1991 A
4995714 Cohen Feb 1991 A
4995715 Cohen Feb 1991 A
5017000 Cohen May 1991 A
5037485 Chromecek et al. Aug 1991 A
5044743 Ting Sep 1991 A
5073021 Marron Dec 1991 A
5106180 Marie et al. Apr 1992 A
5121979 Cohen Jun 1992 A
5142411 Fiala Aug 1992 A
5144483 Cohen Sep 1992 A
5158572 Nielsen Oct 1992 A
5257132 Ceglio et al. Oct 1993 A
5278592 Marie et al. Jan 1994 A
5331394 Shalon et al. Jul 1994 A
5344447 Swanson Sep 1994 A
5410375 Fiala Apr 1995 A
5517260 Glady et al. May 1996 A
5623322 Hirschman et al. Apr 1997 A
5682223 Menezes et al. Oct 1997 A
5718849 Maus et al. Feb 1998 A
5750060 Maus et al. May 1998 A
5750156 Maus et al. May 1998 A
5760871 Kosoburd et al. Jun 1998 A
5782911 Herrick Jul 1998 A
5806530 Herrick Sep 1998 A
5821943 Shashua Oct 1998 A
5838496 Maruyama Nov 1998 A
5855605 Herrick Jan 1999 A
5861934 Blum et al. Jan 1999 A
5875017 Ohnuma et al. Feb 1999 A
5968094 Werbin et al. Oct 1999 A
5982543 Fiala Nov 1999 A
6010215 Miceli Jan 2000 A
6024902 Maus et al. Feb 2000 A
6068464 Su et al. May 2000 A
6082987 Su et al. Jul 2000 A
6086203 Blum et al. Jul 2000 A
6099763 Su et al. Aug 2000 A
6103148 Su et al. Aug 2000 A
6106118 Menezes et al. Aug 2000 A
6123422 Menezes et al. Sep 2000 A
6139145 Israel Oct 2000 A
6139148 Menezes Oct 2000 A
6149271 Menezes et al. Nov 2000 A
6199984 Menezes Mar 2001 B1
6231184 Menezes et al. May 2001 B1
6288846 Stoner, Jr. Sep 2001 B1
D449321 Su Oct 2001 S
6312424 Largent Nov 2001 B1
6357875 Herrick Mar 2002 B1
6358280 Herrick Mar 2002 B1
6364483 Grossinger et al. Apr 2002 B1
6365074 Su Apr 2002 B1
6390623 Kokonaski et al. May 2002 B1
6474814 Griffin Nov 2002 B1
6505934 Menezes Jan 2003 B1
6536899 Fiala Mar 2003 B1
6630083 Nunez et al. Oct 2003 B1
6638304 Azar Oct 2003 B2
6685315 De Carle Feb 2004 B1
6709105 Menezes Mar 2004 B2
6855164 Glazier Feb 2005 B2
6883916 Menezes Apr 2005 B2
6932839 Kamerling et al. Aug 2005 B1
6951391 Morris et al. Oct 2005 B2
7025456 Morris et al. Apr 2006 B2
7041133 Azar May 2006 B1
7073906 Portney Jul 2006 B1
7093938 Morris et al. Aug 2006 B2
7141065 Azar Nov 2006 B2
7144423 McDonald Dec 2006 B2
7152975 Ho et al. Dec 2006 B2
7156516 Morris et al. Jan 2007 B2
7159983 Menezes et al. Jan 2007 B2
7178918 Griffin Feb 2007 B2
7229173 Menezes Jun 2007 B2
7229475 Glazier Jun 2007 B2
7232218 Morris et al. Jun 2007 B2
7256921 Kumar et al. Aug 2007 B2
7261736 Azar Aug 2007 B1
7270677 Azar Sep 2007 B2
7281795 Sandstedt et al. Oct 2007 B2
7286275 Kumar et al. Oct 2007 B2
7331668 Azar et al. Feb 2008 B2
7334892 Goodall et al. Feb 2008 B2
7334894 Hillis et al. Feb 2008 B2
RE40152 Maus et al. Mar 2008 E
7338161 Chauveau et al. Mar 2008 B2
7341345 Azar et al. Mar 2008 B2
7342112 Kumar et al. Mar 2008 B2
7344244 Goodall et al. Mar 2008 B2
7349137 Kumar et al. Mar 2008 B2
7349138 Kumar et al. Mar 2008 B2
7350919 Hillis et al. Apr 2008 B2
7359104 Kumar et al. Apr 2008 B2
7364294 Menezes Apr 2008 B2
7377641 Piers et al. May 2008 B2
7390088 Goodall et al. Jun 2008 B2
7394585 Kumar et al. Jul 2008 B2
7429105 Kumar et al. Sep 2008 B2
7318642 Menezes Oct 2008 B2
7441894 Zhang et al. Oct 2008 B2
7452075 Iuliano Nov 2008 B2
7457025 Kumar et al. Nov 2008 B2
7457434 Azar Nov 2008 B2
7465415 Wang et al. Dec 2008 B2
7466469 Kumar et al. Dec 2008 B2
7470027 Hillis et al. Dec 2008 B2
7471436 Kumar et al. Dec 2008 B2
7481532 Hong et al. Jan 2009 B2
7481955 Xiao Jan 2009 B2
7486988 Goodall et al. Feb 2009 B2
7505189 Kumar et al. Mar 2009 B2
7527754 Chopra May 2009 B2
7543937 Piers et al. Jun 2009 B2
7553925 Bojkova Jun 2009 B2
7556381 Kelch et al. Jul 2009 B2
7557206 Kumar et al. Jul 2009 B2
7560124 Kumar et al. Jul 2009 B2
7579022 Kumar et al. Aug 2009 B2
7582749 Kumar et al. Sep 2009 B2
7594727 Hillis et al. Sep 2009 B2
7623295 Sabeta Nov 2009 B2
7632540 Kumar et al. Dec 2009 B2
7641337 Altmann Jan 2010 B2
7655002 Myers Feb 2010 B2
7656569 Hillis et al. Feb 2010 B2
7666510 Stewart Feb 2010 B2
7687597 Bojkova Mar 2010 B2
7696296 Bojkova et al. Apr 2010 B2
7699464 Iuliano Apr 2010 B2
7717558 Hong et al. May 2010 B2
7728949 Clarke et al. Jun 2010 B2
7812295 Zalevsky et al. Oct 2010 B2
7819523 Shimojo Oct 2010 B2
7828430 Ballet et al. Nov 2010 B2
7828431 Ho et al. Nov 2010 B2
7832857 Levinson et al. Nov 2010 B2
7833442 Chen et al. Nov 2010 B2
7847998 Kumar et al. Dec 2010 B2
7850879 Cheb et al. Dec 2010 B2
7883206 Blum et al. Feb 2011 B2
7888436 Szymanski et al. Feb 2011 B2
7891809 Ballet et al. Feb 2011 B2
7901076 Azar et al. Mar 2011 B2
7906214 Seybert et al. Mar 2011 B2
7910019 He et al. Mar 2011 B2
7910020 He et al. Mar 2011 B2
7926940 Blum et al. Apr 2011 B2
7931373 Hillis et al. Apr 2011 B2
7978391 Kumar et al. Jul 2011 B2
7988285 Sandstedt et al. Aug 2011 B2
8003005 He et al. Aug 2011 B2
8038711 Clarke Oct 2011 B2
8077373 Kumar et al. Dec 2011 B2
8084133 Colton Dec 2011 B2
8089678 Kumar et al. Jan 2012 B2
8100527 Hong et al. Jan 2012 B2
8104892 Hillis et al. Jan 2012 B2
8109632 Hillis et al. Feb 2012 B2
8153344 Faler et al. Apr 2012 B2
8211338 He et al. Jul 2012 B2
8215770 Blum et al. Jul 2012 B2
8216308 Blake et al. Jul 2012 B2
8216309 Azar Jul 2012 B2
8220477 Park Jul 2012 B2
8231217 Ballet et al. Jul 2012 B2
8235525 Lesage et al. Aug 2012 B2
8240850 Apter et al. Aug 2012 B2
8244342 Goodall et al. Aug 2012 B2
8262727 McDonald Sep 2012 B2
8262728 Zhang et al. Sep 2012 B2
8267515 Azar et al. Sep 2012 B2
8282212 Hillis et al. Oct 2012 B2
8308295 Blum et al. Nov 2012 B2
8319937 Clarke et al. Nov 2012 B2
8349210 Xu et al. Jan 2013 B2
8431039 Dia et al. Apr 2013 B2
8434865 Blum et al. May 2013 B2
8475529 Clake Jul 2013 B2
8507050 Faler et al. Aug 2013 B2
8518546 He et al. Aug 2013 B2
8535577 Chopra et al. Sep 2013 B2
8545015 Kumar et al. Oct 2013 B2
8545984 He et al. Oct 2013 B2
8556416 Lawu Oct 2013 B2
8562540 Goodall et al. Oct 2013 B2
8563212 Bowles et al. Oct 2013 B2
8563213 Bowles et al. Oct 2013 B2
8582192 Kumar et al. Nov 2013 B2
8587734 Li Nov 2013 B2
8608800 Portney Dec 2013 B2
8613868 Dai et al. Dec 2013 B2
8619362 Portney Dec 2013 B2
8623238 Xu et al. Jan 2014 B2
8628685 He et al. Jan 2014 B2
8647538 Lu et al. Feb 2014 B2
8649081 DeMeio et al. Feb 2014 B1
8678583 Cohen Mar 2014 B2
8698117 He et al. Apr 2014 B2
8705160 He et al. Apr 2014 B2
8747466 Weeber et al. Jun 2014 B2
8779168 He et al. Jul 2014 B2
8789951 Thompson et al. Jul 2014 B2
8807746 Kato et al. Aug 2014 B2
8828284 Carpenter Sep 2014 B2
8828296 Zhang et al. Sep 2014 B2
8828507 He et al. Sep 2014 B2
8848288 Retsch, Jr. Sep 2014 B2
8859097 Chopra Oct 2014 B2
8871016 Trexler et al. Oct 2014 B2
8882264 Bradley et al. Nov 2014 B2
8885139 Peyghambarian et al. Nov 2014 B2
8888277 Jubin et al. Nov 2014 B2
8889807 Hickenboth et al. Nov 2014 B2
8894203 Bradley et al. Nov 2014 B2
8894204 Weeber et al. Nov 2014 B2
8894706 Portney Nov 2014 B2
8920928 He et al. Dec 2014 B2
8926091 Kumar et al. Jan 2015 B2
8992610 Blum et al. Mar 2015 B2
9001316 Mohan et al. Apr 2015 B2
9028728 Bancroft et al. May 2015 B2
9029532 Dabideen et al. May 2015 B2
9029565 He et al. May 2015 B1
9030740 DeMeio et al. May 2015 B2
9034219 He et al. May 2015 B2
9040648 Hickenboth et al. May 2015 B2
9045647 Kleyer et al. Jun 2015 B2
9051332 He et al. Jun 2015 B1
9051426 Hickenboth et al. Jun 2015 B2
9062213 Bradford et al. Jun 2015 B2
9081208 Blum et al. Jul 2015 B2
9091864 Kingston et al. Jul 2015 B2
9096014 Kumar et al. Aug 2015 B2
9096026 Hall et al. Aug 2015 B2
9101466 Hong Aug 2015 B2
9116363 Pugh et al. Aug 2015 B2
9122083 Blum et al. Sep 2015 B2
9139552 Xiao et al. Sep 2015 B2
9146407 Clarke et al. Sep 2015 B2
9155483 Hillis et al. Oct 2015 B2
9173717 Tripathi Nov 2015 B2
9175153 Trexler et al. Nov 2015 B2
9206151 He et al. Dec 2015 B2
9216080 Bogaert et al. Dec 2015 B2
9223148 Fiala et al. Dec 2015 B2
9226798 Tripathi et al. Jan 2016 B2
9259309 Fehr et al. Feb 2016 B2
9259310 Schachar et al. Feb 2016 B2
9277988 Chu Mar 2016 B1
9279907 Bojkova Mar 2016 B2
9304329 Zhao Apr 2016 B2
9309455 He et al. Apr 2016 B2
9320594 Schwiegerling Apr 2016 B2
9323073 Pugh et al. Apr 2016 B2
9332899 Shea et al. May 2016 B2
9334345 Herold et al. May 2016 B2
9334439 DeMeio et al. May 2016 B2
9335564 Choi et al. May 2016 B2
9405041 He et al. Aug 2016 B2
9411076 Slezak et al. Aug 2016 B2
9427313 Currie Aug 2016 B2
9433496 Clough Sep 2016 B2
9441080 Trexler et al. Sep 2016 B2
9454021 Guillon et al. Sep 2016 B2
9459470 Hillis et al. Oct 2016 B2
9469731 Bojkova Oct 2016 B2
9474594 Schachar et al. Oct 2016 B2
9475901 Saha et al. Oct 2016 B2
9523004 Hervieu et al. Dec 2016 B2
9526656 Serdarevic et al. Dec 2016 B2
9532904 Serdarevic et al. Jan 2017 B2
9545339 Serdarevic et al. Jan 2017 B2
9563070 Ando et al. Feb 2017 B2
9568643 Bojkova et al. Feb 2017 B2
9568744 Pugh et al. Feb 2017 B2
9588396 Haddock et al. Mar 2017 B2
9594259 Brennan et al. Mar 2017 B2
9630902 He et al. Apr 2017 B2
9658471 Ando et al. May 2017 B2
9664923 Wildsmith et al. May 2017 B2
9675444 Blum et al. Jun 2017 B2
9690021 Turpen et al. Jun 2017 B2
9693679 Dorronsoro Diaz et al. Jul 2017 B2
9724190 Weeber et al. Aug 2017 B2
9733488 Ambler et al. Aug 2017 B2
9733489 Paille et al. Aug 2017 B2
9770326 Bradley et al. Sep 2017 B2
9782064 Linder et al. Oct 2017 B1
9891349 Bojkova et al. Feb 2018 B2
9895260 Schachar et al. Feb 2018 B2
9927633 Franklin et al. Mar 2018 B2
9955862 Freeman et al. May 2018 B2
9963546 Bhagwager et al. May 2018 B2
9987127 Bogaert et al. Jun 2018 B2
10000472 He et al. Jun 2018 B2
10005763 He et al. Jun 2018 B2
10007038 Kumar et al. Jun 2018 B2
10010406 Sandstedt et al. Jul 2018 B2
10012773 Bojkova et al. Jul 2018 B2
10012848 Brennan et al. Jul 2018 B2
10039635 Wanders Aug 2018 B2
10052195 Blum et al. Aug 2018 B2
10061143 Brennan et al. Aug 2018 B2
10085833 Piers et al. Oct 2018 B2
10111583 Freeman et al. Oct 2018 B1
10114235 Blum et al. Oct 2018 B2
10145996 DeMeio et al. Dec 2018 B2
10155858 Bhagwagar et al. Dec 2018 B2
10175508 Ambier et al. Jan 2019 B2
10185057 Colton et al. Jan 2019 B2
10209533 Schwiegerling Feb 2019 B2
10213358 Dorronsoro Diaz et al. Feb 2019 B2
10219893 Currie et al. Mar 2019 B2
10226327 Fernandez Gutierrez et al. Mar 2019 B2
10278809 Gerlach May 2019 B2
10278810 Clamen et al. May 2019 B2
10278811 Choi et al. May 2019 B2
10281628 Koenig, II et al. May 2019 B2
10285806 Choi et al. May 2019 B2
10295841 Ando May 2019 B2
10302968 Waite et al. May 2019 B2
10308618 Fromentin et al. Jun 2019 B2
10342700 Schachar et al. Jul 2019 B2
10371866 Frease et al. Aug 2019 B2
10398544 Sayegh Sep 2019 B2
10409088 Hillis et al. Sep 2019 B2
10420638 Hong et al. Sep 2019 B2
10423061 Tomasulo et al. Sep 2019 B2
10426599 Choi et al. Oct 2019 B2
10444537 Kumar et al. Oct 2019 B2
10444543 Thompson Oct 2019 B2
10463474 Lux et al. Nov 2019 B2
10466487 Blum et al. Nov 2019 B2
10473822 Fan et al. Nov 2019 B2
10493486 Lynch et al. Dec 2019 B2
10501446 He et al. Dec 2019 B2
10501477 Deng et al. Dec 2019 B2
10517716 Luque Dec 2019 B2
10524899 Lux et al. Jan 2020 B2
10532997 He et al. Jan 2020 B2
10532998 He et al. Jan 2020 B2
10543577 Masad et al. Jan 2020 B2
10564448 Ando Feb 2020 B2
10568734 Mackool Feb 2020 B2
10571611 Koenig, II et al. Feb 2020 B2
10590220 Saha et al. Mar 2020 B2
10598960 Blum et al. Mar 2020 B2
10619018 Kumar et al. Apr 2020 B2
10619098 Reddy et al. Apr 2020 B2
10646329 Zhao May 2020 B2
10649234 Zhao May 2020 B2
10670885 Zhao Jun 2020 B2
10675146 Choi et al. Jun 2020 B2
10688522 Lynch et al. Jun 2020 B2
10698234 Zhao Jun 2020 B2
10709546 Peyman Jul 2020 B2
10712589 Zhao Jul 2020 B2
10725320 Schwiegerling Jul 2020 B2
10747021 Franklin et al. Aug 2020 B2
10747022 Ando et al. Aug 2020 B2
10765510 Sarver et al. Sep 2020 B2
10786959 Damodharan et al. Sep 2020 B2
10835374 Barzilay Nov 2020 B2
10838111 Fromentin Nov 2020 B2
10842617 Hong et al. Nov 2020 B2
10849736 Neuhann et al. Dec 2020 B2
10874297 Freeman et al. Dec 2020 B1
10874505 Sandstedt et al. Dec 2020 B2
10875833 Kumar et al. Dec 2020 B2
10884246 Blum et al. Jan 2021 B2
10884288 He et al. Jan 2021 B2
10905543 Ghabra et al. Feb 2021 B2
10912457 Schmeder Feb 2021 B2
10932901 Zheleznyak et al. Mar 2021 B2
10993798 Choi et al. May 2021 B2
10994563 Frease et al. May 2021 B2
11000361 Hong et al. May 2021 B2
11000365 Choi et al. May 2021 B2
11000366 Choi et al. May 2021 B2
11009723 Ando May 2021 B2
11029536 Lux et al. Jun 2021 B2
11039901 Tripathi Jun 2021 B2
11051884 Tripathi et al. Jul 2021 B2
11076987 Schachar et al. Aug 2021 B2
11084236 Turpen et al. Aug 2021 B2
11103344 Zhang Aug 2021 B2
11123178 Zhao Sep 2021 B2
11129707 Pagnoulle et al. Sep 2021 B2
11130912 Kumar et al. Sep 2021 B2
11135052 Goldshleger et al. Oct 2021 B2
11143887 Waite et al. Oct 2021 B2
20010027315 Largent Oct 2001 A1
20020093701 Zhang et al. Jul 2002 A1
20020101564 Herrick Aug 2002 A1
20020196410 Menezes Dec 2002 A1
20030018383 Azar Jan 2003 A1
20030081171 Griffin May 2003 A1
20030093149 Glazier May 2003 A1
20030099330 Mery et al. May 2003 A1
20030151831 Sandstedt et al. Aug 2003 A1
20030187505 Liao Oct 2003 A1
20040075807 Ho et al. Apr 2004 A1
20040080711 Menezes Apr 2004 A1
20040082995 Woods Apr 2004 A1
20040199149 Myers et al. Oct 2004 A1
20040252274 Morris et al. Dec 2004 A1
20050003107 Kumar et al. Jan 2005 A1
20050004361 Kumar et al. Jan 2005 A1
20050012998 Kumar et al. Jan 2005 A1
20050021138 Woods Jan 2005 A1
20050021140 Liao Jan 2005 A1
20050057720 Morris et al. Mar 2005 A1
20050068493 Menezes Mar 2005 A1
20050068494 Griffin Mar 2005 A1
20050071002 Glazier Mar 2005 A1
20050099597 Sandstedt et al. May 2005 A1
20050140922 Bekerman et al. May 2005 A1
20050168689 Knox Aug 2005 A1
20050182490 McDonald Aug 2005 A1
20050187622 Sandstedt et al. Aug 2005 A1
20050259222 Kelch et al. Nov 2005 A1
20050264757 Morris et al. Dec 2005 A1
20060014099 Faler et al. Jan 2006 A1
20060022176 Wang et al. Feb 2006 A1
20060023162 Azar et al. Feb 2006 A1
20060050234 Morris et al. Mar 2006 A1
20060050236 Menezes Mar 2006 A1
20060055883 Morris et al. Mar 2006 A1
20060066808 Blum et al. Mar 2006 A1
20060089713 Azar Apr 2006 A1
20060092375 Menezes et al. May 2006 A1
20060100704 Blake et al. May 2006 A1
20060116764 Simpson Jun 2006 A1
20060116765 Blake et al. Jun 2006 A1
20060119793 Hillis et al. Jun 2006 A1
20060119794 Hillis et al. Jun 2006 A1
20060122530 Goodall et al. Jun 2006 A1
20060122531 Goodall et al. Jun 2006 A1
20060146281 Goodall et al. Jul 2006 A1
20060164593 Peyghambarian et al. Jul 2006 A1
20060176449 Azar et al. Aug 2006 A1
20060203189 Ho et al. Sep 2006 A1
20060206204 Azar Sep 2006 A1
20060206205 Azar Sep 2006 A1
20060224238 Azar Oct 2006 A1
20060244906 Piers et al. Nov 2006 A1
20060293747 McDonald Dec 2006 A1
20070010757 Goodall et al. Jan 2007 A1
20070019157 Hillis et al. Jan 2007 A1
20070019272 Hillis et al. Jan 2007 A1
20070019279 Goodall et al. Jan 2007 A1
20070021831 Clarke Jan 2007 A1
20070028931 Hillis et al. Feb 2007 A1
20070030444 Chauveau et al. Feb 2007 A1
20070030445 Menezes Feb 2007 A1
20070041071 Kumar et al. Feb 2007 A1
20070041073 Kumar et al. Feb 2007 A1
20070047053 Kumar et al. Mar 2007 A1
20070047054 Kumar et al. Mar 2007 A1
20070047055 Kumar et al. Mar 2007 A1
20070053047 Kumar et al. Mar 2007 A1
20070053048 Kumar et al. Mar 2007 A1
20070053049 Kumar et al. Mar 2007 A1
20070053050 Kumar et al. Mar 2007 A1
20070054131 Stewart Mar 2007 A1
20070067030 Glazier et al. Mar 2007 A1
20070075388 Kumar et al. Apr 2007 A1
20070076167 Kumar et al. Apr 2007 A1
20070098968 Kumar et al. May 2007 A1
20070138448 Chopra Jun 2007 A1
20070138665 Chen et al. Jun 2007 A1
20070145337 Chopra Jun 2007 A1
20070153231 Iuliano Jul 2007 A1
20070177100 Knox Aug 2007 A1
20070182917 Zhang et al. Aug 2007 A1
20070182921 Zhang et al. Aug 2007 A1
20070182924 Hong Aug 2007 A1
20070216863 Menzes Sep 2007 A1
20070258143 Portney Nov 2007 A1
20070260307 Azar Nov 2007 A1
20070270548 Bojkova et al. Nov 2007 A1
20070270549 Szymanski et al. Nov 2007 A1
20070274626 Sabeta Nov 2007 A1
20070275098 Banks Nov 2007 A1
20070278460 Xiao Dec 2007 A1
20070278461 Petrovskaia et al. Dec 2007 A1
20070286969 Nagpal et al. Dec 2007 A1
20070291345 Kumar et al. Dec 2007 A1
20080045704 Kumar et al. Feb 2008 A1
20080051575 Kumar et al. Feb 2008 A1
20080086207 Sandstedt et al. Apr 2008 A1
20080095933 Colton et al. Apr 2008 A1
20080096023 Colton et al. Apr 2008 A1
20080096048 Kumar et al. Apr 2008 A1
20080096049 Kumar et al. Apr 2008 A1
20080123172 Kumar et al. May 2008 A1
20080125525 Bojkova May 2008 A1
20080125570 Bojkova May 2008 A1
20080137031 Hillis et al. Jun 2008 A1
20080151183 Altmann Jun 2008 A1
20080160318 Senkfor et al. Jul 2008 A1
20080161673 Goodall et al. Jul 2008 A1
20080180630 Clarke et al. Jul 2008 A1
20080180803 Seybert et al. Jul 2008 A1
20080187749 Cael et al. Aug 2008 A1
20080198326 Piers et al. Aug 2008 A1
20080198331 Azar et al. Aug 2008 A1
20080206579 LaLumere et al. Aug 2008 A1
20080212017 Ballet et al. Sep 2008 A1
20080212023 Bovet et al. Sep 2008 A1
20080218689 Blum et al. Sep 2008 A1
20080231799 Iuliano Dec 2008 A1
20080297720 Ballet et al. Dec 2008 A1
20090033863 Blum et al. Feb 2009 A1
20090082859 Azar Mar 2009 A1
20090088840 Simpson Apr 2009 A1
20090096981 Clarke et al. Apr 2009 A1
20090122262 Hong et al. May 2009 A1
20090124721 Chen et al. May 2009 A1
20090125105 Lesage et al. May 2009 A1
20090135462 Kumar et al. May 2009 A1
20090146104 He et al. Jun 2009 A1
20090147378 Zelevsky et al. Jun 2009 A1
20090187242 Weeber et al. Jul 2009 A1
20090189830 Deering et al. Jul 2009 A1
20090195751 Hillis et al. Aug 2009 A1
20090204207 Blum et al. Aug 2009 A1
20090239043 Kondos et al. Sep 2009 A1
20090240328 Treushnikov et al. Sep 2009 A1
20090268155 Weeber Oct 2009 A1
20090303433 Shimojo Dec 2009 A1
20090309076 He et al. Dec 2009 A1
20090323011 He et al. Dec 2009 A1
20090323012 He et al. Dec 2009 A1
20100016962 Hong et al. Jan 2010 A1
20100035067 Colton Feb 2010 A1
20100039612 Levinson et al. Feb 2010 A1
20100065625 Sabeta Mar 2010 A1
20100066973 Portney Mar 2010 A1
20100076554 Sandstedt et al. Mar 2010 A1
20100094262 Tripathi et al. Apr 2010 A1
20100103373 Hillis et al. Apr 2010 A1
20100114079 Myers et al. May 2010 A1
20100118260 Ballet et al. May 2010 A1
20100119735 Faler et al. May 2010 A1
20100134754 Hong Jun 2010 A1
20100157241 Kumar et al. Jun 2010 A1
20100161051 Hong Jun 2010 A1
20100177279 Hillis et al. Jul 2010 A1
20100188636 Pinto et al. Jul 2010 A1
20100209697 Bowles et al. Aug 2010 A1
20100217278 Tripathi Aug 2010 A1
20100221661 Bowles et al. Sep 2010 A1
20100225834 Li Sep 2010 A1
20100259719 Sabeta Oct 2010 A1
20100281021 Weeber et al. Nov 2010 A1
20100286771 Zhang et al. Nov 2010 A1
20100321635 Apter et al. Dec 2010 A1
20110023924 Park Feb 2011 A1
20110080628 Kumar et al. Apr 2011 A1
20110112634 Azar et al. May 2011 A1
20110128457 He et al. Jun 2011 A1
20110129678 He et al. Jun 2011 A1
20110135850 Saha et al. Jun 2011 A1
20110140056 He et al. Jun 2011 A1
20110143141 He et al. Jun 2011 A1
20110157548 Lesage et al. Jun 2011 A1
20110166652 Bogaert et al. Jul 2011 A1
20110194069 Blum et al. Aug 2011 A1
20110216273 He et al. Sep 2011 A1
20110234974 Lawu Sep 2011 A1
20110270389 Glazer et al. Nov 2011 A1
20110279883 Kumar et al. Nov 2011 A1
20110285959 Gupta et al. Nov 2011 A1
20110292335 Schwiegerling Dec 2011 A1
20120002141 Dai et al. Jan 2012 A1
20120003401 Xu et al. Jan 2012 A1
20120016350 Myers et al. Jan 2012 A1
20120021144 Dai et al. Jan 2012 A1
20120027960 Xu et al. Feb 2012 A1
20120035724 Clarke Feb 2012 A1
20120061863 Cox et al. Mar 2012 A1
20120086910 Kato et al. Apr 2012 A1
20120092613 Azar Apr 2012 A1
20120120473 Kumar et al. May 2012 A1
20120126185 He et al. May 2012 A1
20120132870 Xiao et al. May 2012 A1
20120136148 Lu et al. May 2012 A1
20120140166 Zhao Jun 2012 A1
20120140167 Blum Jun 2012 A1
20120145973 Bancroft et al. Jun 2012 A1
20120154740 Bradley et al. Jun 2012 A1
20120156508 He et al. Jun 2012 A1
20120156521 He et al. Jun 2012 A1
20120157677 He et al. Jun 2012 A1
20120176581 Bradley et al. Jul 2012 A1
20120179248 Azar Jul 2012 A1
20120183810 Chopra Jul 2012 A1
20120200907 He et al. Aug 2012 A1
20120206691 Ivai Aug 2012 A1
20120212696 Trajkovska et al. Aug 2012 A1
20120214992 Chopra et al. Aug 2012 A1
20120224138 Cohen Sep 2012 A1
20120224139 Retsch, Jr. Sep 2012 A1
20120236257 Hillis et al. Sep 2012 A1
20120267030 Hall et al. Oct 2012 A1
20120286435 Bojkova et al. Nov 2012 A1
20120320335 Weeber et al. Dec 2012 A1
20120323320 Simonov et al. Dec 2012 A1
20120330414 McDonald Dec 2012 A1
20130004780 Hervieu et al. Jan 2013 A1
20130027655 Blum et al. Jan 2013 A1
20130032059 Trexler et al. Feb 2013 A1
20130035760 Portney Feb 2013 A1
20130050640 Fiala et al. Feb 2013 A1
20130050651 Azar et al. Feb 2013 A1
20130069274 Zhang et al. Mar 2013 A1
20130070199 Blum et al. Mar 2013 A1
20130072591 Sandstedt et al. Mar 2013 A1
20130073038 Azar Mar 2013 A1
20130082220 Herold et al. Apr 2013 A1
20130122221 Colton et al. May 2013 A1
20130176536 Thompson et al. Jul 2013 A1
20130208347 Haddock et al. Aug 2013 A1
20130211515 Blum et al. Aug 2013 A1
20130211516 Blum et al. Aug 2013 A1
20130215374 Blum et al. Aug 2013 A1
20130218269 Schachar et al. Aug 2013 A1
20130225777 Hickenboth et al. Aug 2013 A1
20130228100 Kleyer et al. Sep 2013 A1
20130231741 Clarke Sep 2013 A1
20130245754 Blum et al. Sep 2013 A1
20130261744 Gupta et al. Oct 2013 A1
20130273380 Hickenboth et al. Oct 2013 A1
20130274412 Hickenboth et al. Oct 2013 A1
20130278891 Zhao Oct 2013 A1
20130289153 Sandstedt et al. Oct 2013 A1
20130308094 Mohan et al. Nov 2013 A1
20130308186 Cathey, Jr. Nov 2013 A1
20130335701 Canovas Vidal et al. Dec 2013 A1
20130338767 Mazzocchi et al. Dec 2013 A1
20140043672 Clarke et al. Feb 2014 A1
20140055744 Wildsmith et al. Feb 2014 A1
20140066537 Jerome et al. Mar 2014 A1
20140078583 DeMeio et al. Mar 2014 A1
20140080972 Slezak et al. Mar 2014 A1
20140107777 Portney Apr 2014 A1
20140118683 Jubin et al. May 2014 A1
20140125949 Shea et al. May 2014 A1
20140125954 Kingston et al. May 2014 A1
20140148899 Fehr et al. May 2014 A1
20140152953 Guillon et al. Jun 2014 A1
20140154514 He et al. Jun 2014 A1
20140155572 Bojkova Jun 2014 A1
20140166948 He et al. Jun 2014 A1
20140171612 Bojkova et al. Jun 2014 A1
20140178513 Matthews Jun 2014 A1
20140199521 Carpenter Jul 2014 A1
20140232982 Iwai Aug 2014 A1
20140240657 Pugh et al. Aug 2014 A1
20140243972 Wanders Aug 2014 A1
20140256935 Dabideen et al. Sep 2014 A1
20140264979 Park et al. Sep 2014 A1
20140265010 Park et al. Sep 2014 A1
20140272111 Bradford et al. Sep 2014 A1
20140272468 DeMeio et al. Sep 2014 A1
20140277051 Schachar et al. Sep 2014 A1
20140277437 Currie Sep 2014 A1
20140327875 Blum et al. Nov 2014 A1
20140340632 Pugh et al. Nov 2014 A1
20140347624 Ando et al. Nov 2014 A1
20140350672 Hong Nov 2014 A1
20150005877 Wanders Jan 2015 A1
20150022775 Ando et al. Jan 2015 A1
20150029460 Bradley et al. Jan 2015 A1
20150044446 Trexler et al. Feb 2015 A1
20150057748 Azar Feb 2015 A1
20150088253 Doll et al. Mar 2015 A1
20150131056 Paille et al. May 2015 A1
20150133901 Serdarevic et al. May 2015 A1
20150138492 Kumar et al. May 2015 A1
20150141661 He et al. May 2015 A1
20150141662 He et al. May 2015 A1
20150141663 He et al. May 2015 A1
20150152271 Bradford et al. Jun 2015 A1
20150159022 Bradford et al. Jun 2015 A1
20150182331 Blum et al. Jul 2015 A1
20150230979 Serdarevic et al. Aug 2015 A1
20150230985 Serdarevic et al. Aug 2015 A1
20150274910 Kumar et al. Oct 2015 A1
20150331253 Choi et al. Nov 2015 A1
20150342727 Fernandez Gutierrez et al. Dec 2015 A1
20150362748 Pugh et al. Dec 2015 A1
20150368408 Trexler et al. Dec 2015 A1
20150378180 Blum et al. Dec 2015 A1
20160051360 Tripathi Feb 2016 A1
20160060205 He et al. Mar 2016 A1
20160062143 Brennan et al. Mar 2016 A1
20160062145 Brennan et al. Mar 2016 A1
20160085089 Hillis et al. Mar 2016 A1
20160100938 Bogaert et al. Apr 2016 A1
20160113727 Tripathi et al. Apr 2016 A1
20160185910 Bojkova Jun 2016 A1
20160209561 DeMeio et al. Jul 2016 A1
20160216535 Zhao Jul 2016 A1
20160220350 Gerlach Aug 2016 A1
20160220352 Choi et al. Aug 2016 A1
20160238758 Turpen et al. Aug 2016 A1
20160243579 Koenig, II et al. Aug 2016 A1
20160245967 Koenig, II et al. Aug 2016 A1
20160279886 Lynch et al. Sep 2016 A1
20160288157 Lynch et al. Oct 2016 A1
20160296110 Dorronsoro et al. Oct 2016 A1
20160299265 Ghatak et al. Oct 2016 A1
20160302915 Sayegh Oct 2016 A1
20160324628 Gupta et al. Nov 2016 A1
20160324629 Sandstedt et al. Nov 2016 A1
20160332995 He et al. Nov 2016 A1
20160333262 He et al. Nov 2016 A1
20160341978 Schwiegerling Nov 2016 A1
20160363698 Fan et al. Dec 2016 A1
20160377887 Waite et al. Dec 2016 A1
20170002174 Bhagwagar et al. Jan 2017 A1
20170009014 Bhagwagar et al. Jan 2017 A1
20170035609 Schachar et al. Feb 2017 A1
20170037173 Saha et al. Feb 2017 A1
20170042665 Currie et al. Feb 2017 A1
20170075140 Hillis et al. Mar 2017 A1
20170105835 Neuhann et al. Apr 2017 A1
20170123231 Franklin et al. May 2017 A1
20170131570 Thompson May 2017 A1
20170131571 Waite et al. May 2017 A1
20170139230 Ambler et al. May 2017 A1
20170146820 Brennan et al. May 2017 A1
20170146822 Wildsmith et al. May 2017 A1
20170153359 Bojkova et al. Jun 2017 A1
20170209259 Choi et al. Jul 2017 A1
20170213306 Weeber et al. Jul 2017 A9
20170219846 Ando Aug 2017 A1
20170224474 Piers et al. Aug 2017 A1
20170227789 Ando et al. Aug 2017 A1
20170235022 Bojkova et al. Aug 2017 A1
20170239038 Choi et al. Aug 2017 A1
20170252151 Mackool Sep 2017 A1
20170258576 Ghabra et al. Sep 2017 A1
20170261768 Ambler et al. Sep 2017 A1
20170273778 Zhao Sep 2017 A1
20170273779 Zhao Sep 2017 A1
20170273780 Zhao Sep 2017 A1
20170273781 Zhao Sep 2017 A1
20170275534 Reddy et al. Sep 2017 A1
20170276962 Zhao Sep 2017 A1
20170290502 Linder et al. Oct 2017 A1
20170290657 Luque Oct 2017 A1
20170325937 Weeber et al. Nov 2017 A1
20180015678 Damodharan et al. Jan 2018 A1
20180024377 Kumar et al. Jan 2018 A1
20180051037 Deng et al. Feb 2018 A1
20180056615 Turpen et al. Mar 2018 A1
20180086725 Kumar et al. Mar 2018 A1
20180092739 Pagnoulle et al. Apr 2018 A1
20180095190 Frease et al. Apr 2018 A1
20180098694 Schmeder Apr 2018 A1
20180125710 Schachar et al. May 2018 A1
20180127653 Kumar et al. May 2018 A1
20180147050 Choi et al. May 2018 A1
20180147052 Hong et al. May 2018 A1
20180164608 Schmeder et al. Jun 2018 A1
20180171154 Lu et al. Jun 2018 A1
20180180902 Franklin et al. Jun 2018 A1
20180196284 Schmeder et al. Jul 2018 A1
20180210330 Tomasulo et al. Jul 2018 A1
20180243082 Zheleznyak et al. Aug 2018 A1
20180249151 Freeman et al. Aug 2018 A1
20180256317 Bogaert et al. Sep 2018 A1
20180271741 Dorronsoro et al. Sep 2018 A1
20180275428 Ando Sep 2018 A1
20180289469 Lux et al. Oct 2018 A1
20180290408 Park et al. Oct 2018 A1
20180291007 He et al. Oct 2018 A1
20180291008 He et al. Oct 2018 A1
20180291009 He et al. Oct 2018 A1
20180296324 Zhang Oct 2018 A1
20180299599 Kumar et al. Oct 2018 A1
20180299600 Miller et al. Oct 2018 A1
20180303601 Lux et al. Oct 2018 A1
20180311034 Hong et al. Nov 2018 A1
20180321510 Vetro Nov 2018 A1
20180329228 Brennan et al. Nov 2018 A1
20180329229 Brennan et al. Nov 2018 A1
20180329234 Blum et al. Nov 2018 A1
20180344452 Liao et al. Dec 2018 A1
20180348524 Blum et al. Dec 2018 A1
20180348529 Blum et al. Dec 2018 A1
20180368972 Rosen et al. Dec 2018 A1
20190004221 Weeber et al. Jan 2019 A1
20190004331 Weeber et al. Jan 2019 A1
20190029808 Piers et al. Jan 2019 A1
20190041664 Ando Feb 2019 A1
20190047967 Fromentin et al. Feb 2019 A1
20190053893 Currie et al. Feb 2019 A1
20190107647 Fromentin Apr 2019 A1
20190125523 Barzilay May 2019 A1
20190133755 Goldshleger et al. May 2019 A1
20190142576 Goldshleger et al. May 2019 A1
20190142577 Xie May 2019 A1
20190169438 Fromentin et al. Jun 2019 A1
20190212473 Fromentin et al. Jul 2019 A1
20190224000 Choi et al. Jul 2019 A1
20190224001 Choi et al. Jul 2019 A1
20190224803 Masad et al. Jul 2019 A1
20190231518 Sarver et al. Aug 2019 A1
20190247181 Peyman Aug 2019 A1
20190254810 Tiwari et al. Aug 2019 A1
20190290423 Sayegh Sep 2019 A1
20190291128 Zezinka et al. Sep 2019 A1
20190307556 Sarver et al. Oct 2019 A1
20190307557 De Carvalho et al. Oct 2019 A1
20190314148 Lui Oct 2019 A1
20190321163 Clamen et al. Oct 2019 A1
20190339545 Schwiegerling Nov 2019 A1
20190343682 Schachar et al. Nov 2019 A1
20190343683 Zheleznyak et al. Nov 2019 A1
20190345286 Valeri et al. Nov 2019 A1
20190353925 Biskop et al. Nov 2019 A1
20190358027 Hong et al. Nov 2019 A1
20190358919 Kumar et al. Nov 2019 A1
20190361269 Waite et al. Nov 2019 A1
20190365528 Choi et al. Dec 2019 A1
20190374334 Brady et al. Dec 2019 A1
20190375948 Zheng Dec 2019 A1
20190375949 Zheng et al. Dec 2019 A1
20190385342 Freeman et al. Dec 2019 A1
20200009605 Kumar et al. Jan 2020 A1
20200012110 Blum et al. Jan 2020 A1
20200022840 Kahook et al. Jan 2020 A1
20200030081 Lux et al. Jan 2020 A1
20200033666 Li Jan 2020 A1
20200048216 Kumar et al. Feb 2020 A1
20200085569 Kaschke et al. Mar 2020 A1
20200103571 He et al. Apr 2020 A1
20200113736 Bos et al. Apr 2020 A1
20200121450 Sarver et al. Apr 2020 A1
20200122487 Rodriguez et al. Apr 2020 A1
20200172798 Stayshich et al. Jun 2020 A1
20200209649 Holmstrom et al. Jul 2020 A1
20200218089 Dubail et al. Jul 2020 A1
20200218093 Blum et al. Jul 2020 A1
20200253722 Choi et al. Aug 2020 A1
20200268506 Zhao Aug 2020 A1
20200271958 Zhao Aug 2020 A1
20200285075 Zhao Sep 2020 A1
20200292847 Wildsmith et al. Sep 2020 A1
20200292849 Schmeder et al. Sep 2020 A1
20200326562 Zhao Oct 2020 A1
20200333632 Franklin et al. Oct 2020 A1
20200386913 Fromentin et al. Dec 2020 A1
20200391457 Damodharan et al. Dec 2020 A1
20200409178 Zhao Dec 2020 A1
20210002415 Zheng et al. Jan 2021 A1
20210003863 Schwiegerling Jan 2021 A1
20210030532 Hong et al. Feb 2021 A1
20210052368 Smadja et al. Feb 2021 A1
20210055217 Blackburn et al. Feb 2021 A1
20210059812 Kontur et al. Mar 2021 A1
20210077251 Barzilay Mar 2021 A1
20210079009 Walters et al. Mar 2021 A1
20210080755 Balasubramanian et al. Mar 2021 A1
20210116604 Fromentin et al. Apr 2021 A1
20210169640 Kaschke et al. Jun 2021 A1
20210177576 Zheleznyak et al. Jun 2021 A1
20210177577 Zheleznyak et al. Jun 2021 A1
20210177578 Zheleznyak et al. Jun 2021 A1
20210177579 Zheleznyak et al. Jun 2021 A1
20210196520 Zheleznyak et al. Jul 2021 A1
20210220118 Choi et al. Jul 2021 A1
20210228335 Hong et al. Jul 2021 A1
20210228337 Sarver et al. Jul 2021 A1
20210228338 Choi et al. Jul 2021 A1
20210247626 Zakharov et al. Aug 2021 A1
20210251718 Tripathi Aug 2021 A1
20210298893 Sarver et al. Sep 2021 A1
20210318556 Shimojo et al. Oct 2021 A1
20210341760 Burgos et al. Nov 2021 A1
Foreign Referenced Citations (98)
Number Date Country
2007219322 Oct 2007 AU
2007219323 Oct 2007 AU
2008200665 Mar 2008 AU
2011218693 Sep 2011 AU
2012100457 May 2012 AU
2012201991 May 2012 AU
2013200699 Feb 2013 AU
2013200702 Feb 2013 AU
2013202083 Apr 2013 AU
2015201867 Apr 2013 AU
2017228616 Apr 2018 AU
102016011774-7 Dec 2017 BR
1275553 Oct 1990 CA
2037556 Sep 1991 CA
2388766 Dec 2003 CA
2678025 Aug 2009 CA
2824656 Jul 2012 CA
1021990 Sep 1993 CN
100543518 Sep 2009 CN
108066046 Nov 2019 CN
209808722 Dec 2019 CN
209992764 Jan 2020 CN
209992764 Jan 2020 CN
280372 Jan 1996 CZ
3924838 Jul 1989 DE
29924922 Sep 2006 DE
202016105180 Oct 2017 DE
202016105181 Oct 2017 DE
20 2019 000 174 Apr 2019 DE
1063556 Mar 2006 EP
2363426 Sep 2011 EP
2548533 Oct 2013 EP
3375410 Sep 2018 EP
3415118 Dec 2018 EP
3461460 Apr 2019 EP
2208077 May 2005 ES
2277705 Jul 2008 ES
2038020 Jul 1980 GB
2105866 Mar 1983 GB
3814017 May 1996 JP
3347514 Nov 2002 JP
0133917 Apr 1998 KR
10-1754196 Jul 2017 KR
2008054 Dec 2011 NL
2002456 Nov 1993 RU
2012136016 Feb 2014 RU
2682481 Mar 2019 RU
I475278 Mar 2015 TW
691733 Feb 1992 UA
WO-9634365 Oct 1996 WO
WO-9805279 Feb 1998 WO
WO-9956671 Nov 1999 WO
WO-0072051 Nov 2000 WO
WO-02085245 Oct 2002 WO
WO-2005006034 Jan 2005 WO
WO-2006124016 Nov 2006 WO
WO-2017006113 Jan 2007 WO
WO-2007146265 Dec 2007 WO
WO-2009076670 Jun 2009 WO
WO-2011059430 May 2011 WO
WO-2011060047 May 2011 WO
WO-2011080730 Jul 2011 WO
WO-2011107723 Sep 2011 WO
WO-2011163668 Dec 2011 WO
WO-2012083143 Jun 2012 WO
WO-2012138426 Oct 2012 WO
WO-2012167284 Dec 2012 WO
WO-2012170066 Dec 2012 WO
WO-2012170287 Dec 2012 WO
WO-2013163532 Oct 2013 WO
WO-2014120607 Jan 2014 WO
WO-2014058315 Apr 2014 WO
WO-2014065659 May 2014 WO
WO-2014120601 Aug 2014 WO
WO-2014140905 Sep 2014 WO
WO-2014151543 Sep 2014 WO
WO-2014152259 Sep 2014 WO
WO 2015-008502 Jun 2015 WO
WO-2015142559 Sep 2015 WO
WO-2015142561 Sep 2015 WO
WO-2015142562 Sep 2015 WO
WO-2015159374 Oct 2015 WO
WO-2018041098 Mar 2018 WO
WO-2018167099 Sep 2018 WO
WO-2018200717 Nov 2018 WO
WO-2018219671 Dec 2018 WO
WO-2018223150 Dec 2018 WO
WO-2019001724 Jan 2019 WO
WO-2019010874 Jan 2019 WO
WO-2019219334 Apr 2019 WO
WO-2019106031 Jun 2019 WO
WO-2019129348 Jul 2019 WO
WO-2019130030 Jul 2019 WO
WO-2019130031 Jul 2019 WO
WO-2019138411 Jul 2019 WO
WO-2019173836 Sep 2019 WO
2020011250 Jan 2020 WO
WO-2020053864 Mar 2020 WO
Non-Patent Literature Citations (11)
Entry
English Abstract of AU 2013200704-B2 published on Feb. 28, 2013.
English Abstract of AU 2011204781-B2 published on Feb. 2, 2012.
English Abstract of CA-3024244-A1 published on Sep. 10, 2019.
English Abstract of CA-2717328-C published on Apr. 14, 2012.
English Abstract of CN-209808722-U published on Dec. 20, 2019.
English Abstract of ES-2277705-B2 published on Jul. 16, 2007.
English Abstract of JP-3814017-B2 published on May 31, 1996.
Garrard et al. (2008). “Design, Fabrication and Testing of Kinoform Lenses,” Proceedings of the ASPE 44: pp. 558-561.
International Search Report and Written Opinion mailed Aug. 16, 2021, directed to International Application No. PCT/IB2021/054657; 11 pages.
Moreno et al. (Jun. 1997). “High efficiency diffractive lenses: Deduction of kinoform profile,” Am. J. Phys. 65(6): 556-562.
Riedl. “Diamond-turned diffractive optical elements for the infrared: suggestion for specification standardization and manufacturing remarks,” SPIE's 2020 International Symposium on Optical Science, Engineering, and Instrumentation, May 28, 2020, San Diego, California; pp. 257-268.
Related Publications (1)
Number Date Country
20210369445 A1 Dec 2021 US
Provisional Applications (1)
Number Date Country
63032892 Jun 2020 US